Jing-Ling Tang (Jingling Tang)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Tissue Engineering

Hyaluronic Acid

Top Venues

Journal of drug targeting

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jiaxin Liu, Liuqi Zhou, Huijing Cong, Jing Hu, Jing-Ling Tang
Resveratrol-loaded microemulsion based thermosensitive hydrogel for potential topical treatment of the vaginal inflammation. Journal of drug targeting (2024)
Jiaxin Liu, Liuqi Zhou, Huijing Cong, Jing Hu, Jing-Ling Tang
Resveratrol-loaded Microemulsion Based Thermosensitive Hydrogel for Potential Topical Treatment of the Vaginal Inflammation. Journal of drug targeting (2024)
Jiaxin Liu, Liuqi Zhou, Huijing Cong, Jing Hu, Jing-Ling Tang
Resveratrol-loaded microemulsion based thermosensitive hydrogel for potential topical treatment of the vaginal inflammation. Journal of drug targeting 32 (4) (2024)
Jiaxin Liu, Liuqi Zhou, Huijing Cong, Jing Hu, Jing-Ling Tang
Resveratrol-loaded microemulsion based thermosensitive hydrogel for potential topical treatment of the vaginal inflammation. Journal of drug targeting 32 (4) (2024)
Jiaxin Liu, Liuqi Zhou, Huijing Cong, Jing Hu, Jing-Ling Tang
Resveratrol-loaded microemulsion based thermosensitive hydrogel for potential topical treatment of the vaginal inflammation. Journal of drug targeting 32 (4) (2024)
Chenghao Wang, Jia Wang, Xinyu Han, Jiaxin Liu, Mengchao Ma, Siyu Tian, Liying Zhang, Jing-Ling Tang
ultra-small lipid carriers with adjustable release profiles for synergistic treatment of drug-resistant ovarian cancer. Nanotechnology (2021)
Li-Ying Zhang, Jia-Ying Yu, Yan-Long Leng, Ran-Ran Zhu, Hong-Xian Liu, Xin-Yu Wang, Ting-Ting Yang, Yi-Ning Guo, Jing-Ling Tang, Xin-Chen Zhang
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway. Cancer gene therapy (2021)